Company Overview of aTyr Pharma Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.
3545 John Hopkins Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Chief Executive Officer and Director
Total Annual Compensation: $472.8K
Vice President of Clinical Affairs
Total Annual Compensation: $295.0K
Total Annual Compensation: $291.2K
Compensation as of Fiscal Year 2015.
aTyr Pharma Inc. Key Developments
aTyr Pharma, Inc. Announces Encouraging Phase 1b/2 Results for Resolaris in First Rare Myopathy Trial
Mar 30 16
aTyr Pharma Inc. announced results from a Phase 1b/2 clinical trial evaluating Resolaris in adult FSHD (facioscapulohumeral muscular dystrophy) patients. The company is developing Resolaris, a potential first-in-class protein therapeutic, for the treatment of rare myopathies with an immune component (RMICs). The Phase 1b/2 study was designed to evaluate the safety, tolerability, immunogenicity and pharmacokinetic (PK) profile of Resolaris in adult FSHD patients, the Company's first treated RMIC population. In addition, the study also evaluated the utility of exploratory pharmacodynamic (PD) markers (including MRI measurements to quantitate areas of potential muscle inflammation) and clinical assessments (including patient reported outcomes). In this randomized, double-blind, placebo-controlled trial, Resolaris was studied in three dose escalation cohorts (0.3, 1.0, and 3.0 mg/kg) across four sites and 20 patients. In each cohort, patients were randomized at a ratio of 3:1 to receive Resolaris or placebo. Patients in the first two dose cohorts were dosed weekly over a period of one month, and patients in the third cohort were dosed weekly over a period of three months. As planned, the company enrolled a total of four patients in the first cohort and eight patients in each of the second and third cohorts. For the second and third cohorts, inclusion criteria included the presence of at least one skeletal muscle in the legs identified by a non-quantitative MRI technique, which is thought to indicate inflammation. The analysis is based on data available through early March 2016.
aTyr Pharma Inc. Appoints Sanjay Shukla as Chief Medical Officer
Mar 30 16
aTyr Pharma Inc. announced that Sanjay Shukla, MD, MS, has joined the company as Chief Medical Officer. Dr. Shukla will lead
aTyr's clinical efforts to advance its Physiocrine biology therapeutic intervention points and strategically develop meaningful medicines that promote tissue homeostasis for patients with various severe and rare diseases. In Dr. Shukla's most recent role as Vice President and Global Head of Integrated Medical Services for Novartis.
aTyr Pharma Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015
Mar 30 16
aTyr Pharma Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company announced loss from operations of $16,483,000 compared to $6,030,000 for the same period a year ago. Net loss was $16,493,000 compared to $6,038,000 for the same period a year ago. Net loss attributable to common stockholders was $16,493,000 compared to $6,038,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.70 compared to $7.04 for the same period a year ago.
For the year, the company announced loss from operations of $47,616,000 compared to $23,554,000 for the same period a year ago. Net loss was $47,973,000 compared to $24,350,000 for the same period a year ago. Net loss attributable to common stockholders was $47,988,000 compared to $24,766,000 for the same period a year ago. Net loss per share attributable to common stockholders, basic and diluted was $3.03 compared to $29.69 for the same period a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|